The Epidemiology of Hematogenous Candidiasis Caused by Different Candida Species
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The medical records of patients with hematogenous candidiasis at M. D. Anderson Cancer Center (Houston) between 1988 and 1992 were retrospectively reviewed. There were 491 episodes of infection (6 per 1,000 admissions), 79% of which occurred outside the intensive care unit setting. A significant decrease in incidence was observed among patients with leukemia over the study period, together with a relative decrease in Candida albicans and Candida tropicalis infections and an increase in Candida krusei and possibly Candida glabrata infections. In the multivariate analysis, fluconazole prophylaxis provided strong protection against the development of C. tropicalis infection (odds ratio [OR] = 0.08) and C. albicans infection (OR = 0.15), in comparison with protection against infections due to other species, but it was the single most important determinant for the relative increase in C. krusei (OR = 27.07) and C. glabrata (OR = 5.08) infections. In conclusion, there has been a substantial shift in the epidemiology of hematogenous candidiasis caused by different Candida species in recent years. Fluconazole appears to be playing a major role in this observed shift.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Changes in the species distributions of bloodstream isolates in hospitalized patients outside the ICU setting have also been reported (1, 20, 30).”
In the citing paper
“The effects of prior fluconazole use on the distribution of various Candida species causing BSI and, in particular, on the emergence of C. glabrata infections were previously demonstrated for patients with hematologic malignancies (1, 18), although other confounding risk factors have also been described (47, 48).”
In the citing paper
“Other North American and European investigators confirmed these observations in larger hospital settings [10, 11, 13, 20, 22, 25, 26].”
From Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991–2000 (2004) · cites this paper as [10]
In the citing paper
“compared to other Candida species infections, the mortality rate associated with C. glabrata is the highest [19].”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [19]
In the citing paper
“Although the association with fluconazole use and increased isolation of C. glabrata is well known (1, 10, 148, 311, 319), the evidence is strongest for cancer centers and less so for individual nonspecialty hospitals (11, 33, 131, 145, 147, 259).”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [1]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fungemia in a Cancer Hospital: Changing Frequency, Earlier Onset, and Results of Therapy
Horn, R., Wong, B., Kiehn, T. E., & Armstrong, D. (1985) · Clinical Infectious Diseases · doi:10.1093/clinids/7.5.646 · Cited by 480
Candida tropicalis: A Major Pathogen in Immunocompromised Patients
WINGARD, J. R., MERZ, W. G., & SARAL, R. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-4-539 · Cited by 294
Systemic candidiasis in cancer patients.
Maksymiuk, A. W., Thongprasert, S., Hopfer, R. L., Luna, M. D. V., Fainstein, V., & Bodey, G. P. (1984) · PubMed · Cited by 271
Fluconazole and Candida krusei Fungemia
Girmenia, C., Pagano, L., Leone, G., & Martino, P. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.18.2267 · Cited by 19
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
“Meta-analysis of antifungal prophylaxis in nonneutropenic critically ill and surgical patients: comparison of five recent systematic reviews Authors (reference) No. of studies includeda Total no. of patients Patient type Yr Antifungal agent(s) b (no. of studies) Effects of prophylaxis onc: IFI Mortality Resistance Pla…”
BackgroundInfluentialCurrent and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
“, which are becoming increasingly prevalent, is problematic because of the increasing incidence of non-albicans species (1, 188) and the emergence of non-albicans isolates resistant to both amphotericin B and the newer azoles (172).”
BackgroundCandida Infections of Medical Devices
Kojic, E. M., & Darouiche, R. O. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.255-267.2004 · Cited by 1,055
“One study, however, found that neutrophil count rather than underlying disease was the most important risk factor (3).”
BackgroundResultSilva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D. W., & Azeredo, J. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00278.x · Cited by 969
“This is extremely important, because, compared with other NCAC species infection, the mortality rate associated with C. glabrata is the highest (Abi-Said et al., 1997; Krcmery, 1999b).”
ResultHorn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956
“tropicalis [34–41].”
Self-citationFidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953
Epidemiology of Candida species infections in critically ill non-immunosuppressed patients
Eggimann, P., Garbino, J., & Pittet, D. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00801-6 · Cited by 900
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
“2007a), after exposure to azole antifungals (Abi-Said et al. 1997; Goldman et al. 2000; Hachem et al. 2008; Hope et al. 2002; Laverdiere et al. 2000; Marr et al. 2000a; Pelz et al. 2001), and in the ICU setting (Trick et al.”
BackgroundInfluentialAzole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“C. parapsilosis is well known for its threat to the pediatric population, as it is responsible for 17–50% of all fungemia in infants and neonates (Abi-Said et al., 1997; Krcmery et al., 1999).”
BackgroundPappas, P. G., Rex, J. H., Lee, J., Hamill, R. J., Larsen, R. A., Powderly, W., Kauffman, C. A., Hyslop, N., Mangino, J. E., Chapman, S., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376906 · Cited by 845
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance
Krcmery, V., & Barnes, A. J. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2001.1151 · Cited by 733
Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
“Race White 293 (57) 313 (50) 136 (49) 60 (43) 91 (59) 606 (53) Black 190 (37) 280 (45) 126 (46) 79 (56) 52 (34) 470 (41) Other or unknown 33 (6) 33 (5) 13 (5) 2 (1) 10 (7) 67 (6)”
BackgroundInfluentialResistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619
“Several studies have initially incriminated the environmental pressure imposed by exposure to fluconazole [52, 53].”
BackgroundEfflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
“For example, pediatric patients are most likely to be infected with C. albicans or C. parapsilosis (262) and patients with leukemia with C. albicans or C. tropicalis, while HSCT patients are likely to be infected with naturally azole-resistant species such as C. krusei, C. glabrata, or Candida lusitaniae (275) which o…”
BackgroundInfluentialAlmirante, B., Rodríguez, D., Park, B. J., Cuenca-Estrella, M., Planes, A. M., Almela, M., Mensa, J., Sanchez, F., Ayats, J., Gimenez, M., et al. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.4.1829-1835.2005 · Cited by 566
“glabrata BSI was first reported from the United States during the 1990s (1, 22, 33, 41).”
BackgroundResultLeroy, O., Gangneux, J.-P., Montravers, P., Mira, J.-P., Gouin, F., Sollet, J.-P., Carlet, J., Reynes, J., Rosenheim, M., Regnier, B., et al. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e31819efac0 · Cited by 535
“Even if this change has been related to the widespread use of fluconazole in prophylaxis and increased use of invasive procedures (8), the reasons for the species distribution variability and the role of fluconazole are contro-”
BackgroundChanging epidemiology of systemic fungal infections
Richardson, M., & Lass-Flörl, C. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01978.x · Cited by 524
“frequently with increasing patient age [2], after exposure to azole antifungals [22], and in the ICU setting [3].”
BackgroundInfluentialPfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521
“has been linked to utilization of fluconazole prophylaxis (1, 3), and infections attributable to C.”
BackgroundFungal Endocarditis: Evidence in the World Literature, 1965-1995
Ellis, M. E., Al-Abdely, H., Sandridge, A., Greer, W., & Ventura, W. (2001) · Clinical Infectious Diseases · doi:10.1086/317550 · Cited by 505
“albicans species over the years is consistent with the reported emergence of non-albicans species of Candida as a significant fungal pathogen in other settings [23, 24].”
ResultMarr, K. A., Seidel, K., White, T. C., & Bowden, R. A. (2000) · The Journal of Infectious Diseases · doi:10.1086/315193 · Cited by 493
“Other Candida species are often acquired endogenously, through invasion of the gastrointestinal tract [7, 20].”
BackgroundResultEpidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991–2000
Marchetti, O., Bille, J., Fluckiger, U., Eggimann, P., Ruef, C., Garbino, J., Calandra, T., Glauser, M., Tauber, M. G., Pittet, D., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/380637 · Cited by 478
“observed more recently in many US hospitals [9, 10].”
BackgroundResultHistory of the development of azole derivatives
Maertens, J. A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00841.x · Cited by 475
“Although the cause of this changing spectrum is multifactorial and has not been evaluated systematically, the selective pressure resulting from the widespread use of fluconazole has most probably contributed to the higher proportion of non-albicans species [40].”
BackgroundKao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
“glabrata, as agents of candidemia has been attributed to the increasing use of azole drugs and the resulting selection of species less susceptible to these agents [19, 20].”
BackgroundInvasive Fungal Pathogens: Current Epidemiological Trends
Pfaller, M. A., Pappas, P. G., & Wingard, J. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504490 · Cited by 448
“Epidemiology of Invasive Mycoses • CID 2006:43 (Suppl 1) • S5 patient populations studied [12, 24, 46], and use of fluconazole”
BackgroundRangel‐Frausto, M. S., Wiblin, T., Blumberg, H. M., Saiman, L., Patterson, J., Rinaldi, M., Pfaller, M., Edwards, Jr., Jarvis, W., Dawson, J., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/520194 · Cited by 430
“There has also been a consistent increase in the number and rate of Candida infections nationally [6], possibly because of the rapidly changing practice of medicine.”
BackgroundRevisiting the source of candidemia: skin or gut?
Nucci, M., & Anaissie, E. (2001) · Clinical Infectious Diseases · doi:10.1086/323759 · Cited by 424
“parapsilosis is frequently recovered from skin samples [41] and candidemia with this organism occurs more frequently in patients with central venous catheters [42], it is tempting to speculate that contamination of skin near the insertion site of a venous catheter leads to venous catheter colonization, biofilm product…”
BackgroundSelf-citationPfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00192-2 · Cited by 424
“parapsilosis were more likely to be related to the presence of an intravascular catheter and were not influenced by exposure to fluconazole or other antifungal agents (Abi-Said et al. 1997).”
BackgroundInfluentialPfaller, M. A., & Diekema, D. J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.t01-1-00844.x · Cited by 423
“Species distribution among the nine US census regions Although several surveillance studies of candidemia have been conducted in the USA, they have generally not been regionally comprehensive or longitudinal [3,4,6,8,9,16,18].”
BackgroundFluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients
Eggimann, P., Francioli, P., Bille, J., Schneider, R., Wu, M.-M., Chapuis, G., Chiolero, R., Pannatier, A., Schilling, J., Geroulanos, S., et al. (1999) · Critical Care Medicine · doi:10.1097/00003246-199906000-00019 · Cited by 414
Eggimann, P., & Pittet, D. (2001) · Chest · doi:10.1378/chest.120.6.2059 · Cited by 395
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., & The SENTRY Participant Group (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.747-751.2000 · Cited by 378
“glabrata as an important BSI pathogen over the past decade (1, 14, 22, 24, 25, 40).”
BackgroundLortholary, O., Desnos-Ollivier, M., Sitbon, K., Fontanet, A., Bretagne, S., & Dromer, F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01128-10 · Cited by 362
“The relationship between the increased incidence of these species and fluconazole prescription has been debated ever since the introduction of fluconazole as prophylaxis in hematology wards (1, 15, 33, 46) and in ICUs (14).”
BackgroundCinnamaldehyde and its derivatives, a novel class of antifungal agents
Shreaz, S., Wani, W. A., Behbehani, J. M., Raja, V., Irshad, M., Karched, M., Ali, I., Siddiqi, W. A., & Hun, L. T. (2016) · Fitoterapia · doi:10.1016/j.fitote.2016.05.016 · Cited by 345
“Treating fungal infections is a challenging task due to the limited number of effective antifungal drugs, the emergence of drug resistance and elevated renal and liver toxicities [31-35].”
BackgroundNosocomial Fungal Infections: Epidemiology, Infection Control, and Prevention
Alangaden, G. J. (2011) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.11.003 · Cited by 337
“Overall, there has been a recent increase in the proportion of infections caused by nonalbicans Candida spp.(3,10,40) In a recent study from”
InfluentialSanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337
“A recent study retrospectively reviewing medical records of patients with hematogenous candidiasis revealed a relative decrease in C. albicans and C. tropicalis infections, but an increase in C. krusei and C. glabrata infections ( 1 ).”
BackgroundNiche-specific regulation of central metabolic pathways in a fungal pathogen
Barelle, C. J., Priest, C. L., MacCallum, D. M., Gow, N. A. R., Odds, F. C., & Brown, A. J. P. (2006) · Cellular Microbiology · doi:10.1111/j.1462-5822.2005.00676.x · Cited by 336
Epidemiological trends in nosocomial candidemia in intensive care
Bassetti, M., Righi, E., Costa, A., Fasce, R., Molinari, M. P., Rosso, R., Pallavicini, F. B., & Viscoli, C. (2006) · BMC Infectious Diseases · doi:10.1186/1471-2334-6-21 · Cited by 332
Shin, J. H., Kee, S. J., Shin, M. G., Kim, S. H., Shin, D. H., Lee, S. K., Suh, S. P., & Ryang, D. W. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1244-1248.2002 · Cited by 334
“The spectrum of Candida species causing candidemia may vary by region and hospital (1, 10, 15, 17, 18).”
BackgroundPfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00240-x · Cited by 331
Hachem, R., Hanna, H., Kontoyiannis, D., Jiang, Y., & Raad, I. (2008) · Cancer · doi:10.1002/cncr.23466 · Cited by 331
“parapsilosis, even in patients with hematologic malignancies.(25) The changing epidemiology observed in this patient population over time is consistent in the comparisons outlined in Table 4.”
ResultSelf-citationANTIMICROBIAL RESISTANCE IN INTENSIVE CARE UNITS
Fridkin, S. K., & Gaynes, R. P. (1999) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(05)70143-x · Cited by 325
Sanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319
“It is conceivable that the selective pressure of fluconazole, due to the increased use of this antifungal in some hospitals (1, 47), may be responsible for both the emergence of C.”
BackgroundOutcome predictors of 84 patients with hematologic malignancies and Fusarium infection
Nucci, M., Anaissie, E. J., Queiroz‐Telles, F., Martins, C. A., Trabasso, P., Solza, C., Mangini, C., Simões, B. P., Colombo, A. L., Vaz, J., et al. (2003) · Cancer · doi:10.1002/cncr.11510 · Cited by 314
“5 (4–75) Underlying disease Acute myeloid leukemia 29 (35) Acute lymphoid leukemia 18 (21) Chronic myeloid leukemia 13 (15) Myelodysplastic syndrome 7 (8) Non-Hodgkin lymphoma 6 (7) Aplastic anemia 5 (6) Multiple myeloma 3 (4) Chronic lymphocytic leukemia 2 (2) Hodgkin disease 1 (1) Underlying cancer not in complete r…”
BackgroundSelf-citationAntifungal drug resistance to azoles and polyenes
Canuto, M. M., & Rodero, F. G. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00371-7 · Cited by 310
An Overview of Fungal Infections
Garber, G. (2001) · Drugs · doi:10.2165/00003495-200161001-00001 · Cited by 309
“There is some evidence that the use of fluconazole prophylaxis has contributed to this shift inCandida epidemiology among cancer patients,[68,69] although the establishment of a causal relationship remains controversial.”
BackgroundLockhart, S. R., Iqbal, N., Cleveland, A. A., Farley, M. M., Harrison, L. H., Bolden, C. B., Baughman, W., Stein, B., Hollick, R., Park, B. J., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01283-12 · Cited by 299
“To implement appropriate control measures, it is important to understand the epidemiology of BSIs caused by Candida species.”
BackgroundInfluentialPredictors of Adverse Outcome in Cancer Patients with Candidemia
Anaissie, E. J., Rex, J. H., Uzun, Ö., & Vartivarian, S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00030-8 · Cited by 295
Self-citationSingh, N. (2001) · Clinical Infectious Diseases · doi:10.1086/323895 · Cited by 285
“Candida species are currently the fourth most commonly recovered isolates in cases of nosocomial bloodstream infection in the United States.”
BackgroundInfluentialPosaconazole: a broad-spectrum triazole antifungal
Torres, H. A., Hachem, R. Y., Chemaly, R. F., Kontoyiannis, D. P., & Raad, I. I. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70297-8 · Cited by 285
Self-citationFridkin, S. K., Kaufman, D., Edwards, J. R., Shetty, S., Horan, T., & Hospitals, T. N. N. I. S. S. (2006) · Pediatrics · doi:10.1542/peds.2005-1996 · Cited by 284
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Hollis, R. J., Messer, S. A., & Group, F. T. S. P. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.1886-1889.1998 · Cited by 281
“(1) observed that infections due to C.”
Epidemiology of opportunistic fungal infections in Latin America
Nucci, M., Queiroz‐Telles, F., Tobón, A. M., Restrepo, A., & Colombo, A. L. (2010) · Clinical Infectious Diseases · doi:10.1086/655683 · Cited by 280
Candidiasis: Predisposing Factors, Prevention, Diagnosis and Alternative Treatment
Martins, N., Ferreira, I. C. F. R., Barros, L., Silva, S., & Henriques, M. (2014) · Mycopathologia · doi:10.1007/s11046-014-9749-1 · Cited by 277
“but also related to nosocomial infections, and even in healthy population [4, 6–15].”
BackgroundUllmann, A. J., Cornely, O. A., Burchardt, A., Hachem, R., Kontoyiannis, D. P., Töpelt, K., Courtney, R., Wexler, D., Krishna, G., Martinho, M., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.658-666.2006 · Cited by 273
“During the past few decades, a shift has been noted in the epidemiology of fungal infections, with fluconazole-resistant yeasts, such as Candida krusei and Candida glabrata, and echinocandin-resistant molds, such as Fusarium species and zygomycetes, becoming increasingly more common causes of IFI (1, 12, 14, 20, 29, 3…”
BackgroundSelf-citationSipsas, N. V., Lewis, R. E., Tarrand, J., Hachem, R., Rolston, K. V., Raad, I. I., & Kontoyiannis, D. P. (2009) · Cancer · doi:10.1002/cncr.24507 · Cited by 269
Self-citationPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Nagy, E., Dobiasova, S., Rinaldi, M., Barton, R., Veselov, A., & the Global Antifungal Surveillance Group (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01915-07 · Cited by 259
“Candida krusei has been recognized as a potentially multidrug-resistant (MDR) fungal pathogen, due to its intrinsic fluconazole resistance combined with reports of decreased susceptibility to both flucytosine and amphotericin B (1, 2, 3, 6, 20, 22, 23, 26, 37, 39, 47, 61).”
BackgroundPfaller, M. A., Jones, R. N., Doern, G. V., Fluit, A. C., Verhoef, J., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., & Hollis, R. J. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00046-2 · Cited by 264
Winston, D. J., Pakrasi, A., & Busuttil, R. W. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-10-199911160-00003 · Cited by 261
“Patients, n (%) 104 108 Median age (range), y 49 (15–75) 53 (19–74) Sex, n (%) Male 56 (54) 61 (56) Female 48 (46) 47 (44) Underlying disease, n (%) Alcoholic liver disease 30 (29) 25 (23) Chronic hepatitis C 21 (20) 24 (22) Chronic hepatitis B 5 (5) 6 (6) Chronic non-A, non-B hepatitis 13 (12) 9 (8) Cryptogenic cirrh…”
Klotz, S. A., Chasin, B. S., Powell, B., Gaur, N. K., & Lipke, P. N. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.07.001 · Cited by 253
Patients at High Risk of Invasive Fungal Infections: When and How to Treat
Rüping, M. J. G. T., Vehreschild, J. J., & Cornely, O. A. (2008) · Drugs · doi:10.2165/00003495-200868140-00002 · Cited by 253
“have been isolated from (iii) haematological malignancy/neutropenia.[54,56-62] clinical specimens, yielding a total of >500 currently However, patients belonging to one of these groups known Candida spp.”
BackgroundViudes, A., Pemán, J., Cantón, E., Úbeda, P., López-Ribot, J., & Gobernado, M. (2002) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-002-0822-1 · Cited by 250
“On the other hand, except among the population of hematologic patients, hematogenous candidiasis occurred more frequently in ICUs, a finding similar to that reported from previous studies performed in oncologic populations [ 16 ].”
BackgroundResultInfluentialDendritic Cell Interaction with Candida albicans Critically Depends on N-Linked Mannan
Cambi, A., Netea, M. G., Mora-Montes, H. M., Gow, N. A. R., Hato, S. V., Lowman, D. W., Kullberg, B.-J., Torensma, R., Williams, D. L., & Figdor, C. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709334200 · Cited by 247
Garbino, J., Lew, D. P., Romand, J.-A., Hugonnet, S., Auckenthaler, R., & Pittet, D. (2002) · Intensive Care Medicine · doi:10.1007/s00134-002-1540-y · Cited by 246
Candida glabrata, an Emerging Oral Opportunistic Pathogen
Li, L., Redding, S., & Dongari-Bagtzoglou, A. (2007) · Journal of Dental Research · doi:10.1177/154405910708600304 · Cited by 241
Almirante, B., Rodríguez, D., Cuenca-Estrella, M., Almela, M., Sanchez, F., Ayats, J., Alonso-Tarres, C., Rodriguez-Tudela, J. L., Pahissa, A., & the Barcelona Candidemia Project Study Group (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.5.1681-1685.2006 · Cited by 238
“parapsilosis candidemia are not completely known, although indwelling venous catheters and parenteral nutrition have been recognized as specific risk factors (1, 7, 11, 16, 17, 18, 37, 38).”
BackgroundManagement of candidiasis Management of Candida species infections in critically ill patients
Eggimann, P., Garbino, J., & Pittet, D. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00831-4 · Cited by 234
Advances and challenges in management of invasive mycoses
Patterson, T. F. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67381-3 · Cited by 230
Immunopathogenesis of Oropharyngeal Candidiasis in Human Immunodeficiency Virus Infection
de Repentigny, L., Lewandowski, D., & Jolicoeur, P. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.4.729-759.2004 · Cited by 228
“tion in the treatment of patients with acute leukemia (2, 278).”
BackgroundPappas, P. G. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.07.004 · Cited by 227
Increasing prevalence of antimicrobial resistance in intensive care units
Fridkin, S. K. (2001) · Critical Care Medicine · doi:10.1097/00003246-200104001-00002 · Cited by 226
Willems, L., van der Geest, R., & de Beule, K. (2001) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2001.00338.x · Cited by 227
“glabrata, is also increasing, largely because of the widespread use of ̄uconazole (14).”
BackgroundNational Surveillance of Fungemia in Denmark (2004 to 2009)
Arendrup, M. C., Bruun, B., Christensen, J. J., Fuursted, K., Johansen, H. K., Kjældgaard, P., Knudsen, J. D., Kristensen, L., Møller, J., Nielsen, L., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01811-10 · Cited by 223
“tropicalis, which has been associated with hematological malignancy (1, 25, 46, 52), was more commonly isolated from males.”
BackgroundInfluentialChow, J. K., Golan, Y., Ruthazer, R., Karchmer, A. W., Carmeli, Y., Lichtenberg, D., Chawla, V., Young, J., & Hadley, S. (2008) · Clinical Infectious Diseases · doi:10.1086/529435 · Cited by 223
“There are, however, limited data regarding factors associated with such infections [8, 11].”
BackgroundPfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Doern, G. V., Brandt, M. E., & Hajjeh, R. A. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00160-6 · Cited by 216
“Recent studies have confirmed the predominant role of candidiasis among the invasive mycoses as we approach the year 2000 (Abi-Said et al. 1997; Fridkin and Jarvis 1996; Nguyen et al. 1996; Pfaller et al. 1998a-d; Rees et al. 1998).”
BackgroundDoi, A. M., Pignatari, A. C. C., Edmond, M. B., Marra, A. R., Camargo, L. F. A., Siqueira, R. A., da Mota, V. P., & Colombo, A. L. (2016) · PLOS ONE · doi:10.1371/journal.pone.0146909 · Cited by 215
Ahmad, S., Khan, Z., Mustafa, A. S., & Khan, Z. U. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.7.2483-2489.2002 · Cited by 214
“It also underscores the fact that the occurrence of candidemia due to more than one species may be more frequent than what is reported in the literature (1).”
BackgroundLaboratory diagnosis of invasive candidiasis.
Ellepola, A. N. B., & Morrison, C. J. (2005) · PubMed · Cited by 260
Empirical Fluconazole versus Placebo for Intensive Care Unit Patients: A Randomized Trial
Schuster, M. G., Edwards, J. E., Sobel, J. D., Darouiche, R. O., Karchmer, A. W., Hadley, S., Slotman, G., Panzer, H., Biswas, P., & Rex, J. H. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-2-200807150-00004 · Cited by 210
“Digestive Diarrhea 22 (17) 21 (15) Liver function abnormality 11 (8) 15 (11)”
Backgroundvan Asbeck, E. C., Clemons, K. V., & Stevens, D. A. (2009) · Critical Reviews in Microbiology · doi:10.3109/10408410903213393 · Cited by 210
“parapsilosis is a frequent fungal colonizer of the subungual space of healthy volunteers (Abi-Said et al. 1997; McGinley et al. 1988; Weems 1992).”
BackgroundBodey, G. P., Mardani, M., Hanna, H. A., Boktour, M., Abbas, J., Girgawy, E., Hachem, R. Y., Kontoyiannis, D. P., & Raad, I. I. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01130-5 · Cited by 209
Self-citationHigh rate of non-albicans candidemia in Brazilian tertiary care hospitals
Lopes Colombo, A., Nucci, M., Salomão, R., Branchini, M. L. M., Richtmann, R., Derossi, A., & Wey, S. B. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00042-5 · Cited by 201
Husain, S., Tollemar, J., Dominguez, E. A., Baumgarten, K., Humar, A., Paterson, D. L., Wagener, M. M., Kusne, S., & Singh, N. (2003) · Transplantation · doi:10.1097/01.tp.0000065178.93741.72 · Cited by 193
Multilocus Sequence Typing of Candidaglabrata Reveals Geographically EnrichedClades
Dodgson, A. R., Pujol, C., Denning, D. W., Soll, D. R., & Fox, A. J. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.12.5709-5717.2003 · Cited by 190
Increasing Incidence of Candidemia: Results from a 20-Year Nationwide Study in Iceland
Ásmundsdóttir, L. R., Erlendsdóttir, H., & Gottfredsson, M. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.9.3489-3492.2002 · Cited by 188
“The epidemiology of candidemia has been studied primarily in selected hospitals (2, 7, 22); few studies have focused on this problem on a nationwide basis (15, 17).”
BackgroundResultInfluentialManagement and outcome of bloodstream infections due to Candida species in England and Wales
Kibbler, C. C., Seaton, S., Barnes, R. A., Gransden, W. R., Holliman, R. E., Johnson, E. M., Perry, J. D., Sullivan, D. J., & Wilson, J. A. (2003) · Journal of Hospital Infection · doi:10.1016/s0195-6701(03)00085-9 · Cited by 187
Candida glabrata Fungemia: Experience in a Tertiary Care Center
Malani, A., Hmoud, J., Chiu, L., Carver, P. L., Bielaczyc, A., & Kauffman, C. A. (2005) · Clinical Infectious Diseases · doi:10.1086/432939 · Cited by 184
“glabrata is strongest for cancer centers [4, 6, 30] and is less strong but still present in some individual nonspecialty hospitals [8].”
BackgroundNosocomial Candidemia in Non-Neutropenic Patients at an Italian Tertiary Care Hospital
Luzzati, R., Amalfitano, G., Lazzarini, L., Soldani, F., Bellino, S., Solbiati, M., Danzi, M. C., Vento, S., Todeschini, G., Vivenza, C., et al. (2000) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960000325 · Cited by 179
“Of particular concern is the relatively high proportion of Candida parapsilosis isolates, typically associated with the use of indwelling cannulas and hyperalimentation [ 13 ], thus raising the question of adequate infection control practices in our hospital.”
BackgroundDiagnostic Issues, Clinical Characteristics, and Outcomes for Patients with Fungemia
Arendrup, M. C., Sulim, S., Holm, A., Nielsen, L., Nielsen, S. D., Knudsen, J. D., Drenck, N. E., Christensen, J. J., & Johansen, H. K. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00179-11 · Cited by 178
“The association between hematology and fungal species has been addressed by others (1, 32, 56).”
BackgroundInvasive Fungal Infections in the ICU: How to Approach, How to Treat
Paramythiotou, E., Frantzeskaki, F., Flevari, A., Armaganidis, A., & Dimopoulos, G. (2014) · Molecules · doi:10.3390/molecules19011085 · Cited by 175
Candida krusei Fungemia: An Escalating Serious Infection in Immunocompromised Patients
Abbas, J., Bodey, G. P., Hanna, H. A., Mardani, M., Girgawy, E., Abi-Said, D., Whimbey, E., Hachem, R., & Raad, I. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.17.2659 · Cited by 172
Self-citationMesser, S. A., Jones, R. N., & Fritsche, T. R. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.5.1782-1787.2006 · Cited by 172
“Limited therapeutic options for treating these infections, as well as concerns over selection of non-Candida species with reduced susceptibilities to the triazole agents (1, 4, 18), have warranted surveillance for potential resistance development and demonstrated the need for expansion of available antifungal regimens…”
BackgroundThe Changing Face of Fungal Infections in Health Care Settings
Weinstein, R. A., & Fridkin, S. K. (2005) · Clinical Infectious Diseases · doi:10.1086/497138 · Cited by 171
“glabrata infections during the 1990s, compared with historical figures at the same centers [26].”
ResultHorizontal Transmission of Candida parapsilosis Candidemia in a Neonatal Intensive Care Unit
Lupetti, A., Tavanti, A., Davini, P., Ghelardi, E., Corsini, V., Merusi, I., Boldrini, A., Campa, M., & Senesi, S. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.7.2363-2369.2002 · Cited by 171
“Candida species are the fourth most commonly recovered organisms from all blood cultures of hospitalized individuals, with an estimated crude mortality rate of 38 to 75% (1, 16, 18).”
BackgroundPathogenicity and drug resistance in Candida albicans and other yeast species
Mishra, N., Prasad, T., Sharma, N., Payasi, A., Prasad, R., Gupta, D., & Singh, R. (2007) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/amicr.54.2007.3.1 · Cited by 168
“glabrata, was reported [143], some studies reported a reduction in prevalence of C.”
Nosocomial fungal infections: candidemia
Verduyn Lunel, F. M., Meis, J. F. G. M., & Voss, A. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00035-8 · Cited by 169
“1981; Weems 1992) but more often with catheter-related infections (Abi-Said et al. 1997).”
BackgroundFluconazole prophylaxis in critically ill surgical patients: A meta-analysis*
Shorr, A. F., Chung, K., Jackson, W. L., Waterman, P. E., & Kollef, M. H. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000178352.14703.49 · Cited by 166
“albicans infections but has simultaneously led to an increase in infections due to nonalbicans species (9, 10).”
BackgroundCurrent challenges in the management of invasive fungal infections
Lai, C.-C., Tan, C.-K., Huang, Y.-T., Shao, P.-L., & Hsueh, P.-R. (2008) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-007-0595-7 · Cited by 165
Pfaller, M. A., Diekema, D. J., Messer, S. A., Boyken, L., Hollis, R. J., & Jones, R. N. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.1.78-83.2003 · Cited by 165
“krusei is best known for its propensity to emerge in settings where fluconazole is used for Candida prophylaxis (1, 23, 49, 50).”
BackgroundColombo, A. L., Guimarães, T., Silva, L. R. B. F., Monfardini, L. P. D. A., Cunha, A. K. B., Rady, P., Alves, T., & Rosas, R. C. (2007) · Infection Control & Hospital Epidemiology · doi:10.1086/513615 · Cited by 162
“albicans is significant worldwide.(4,5) In stark contrast to 1980-1990 National Nosocomial Infections Surveillance system data from the United States, a recent study that addressed bloodstream infections (BSIs) due to Candida species in intensive care units (ICUs) from 1,116 US medical centers demonstrated a substanti…”
BackgroundResult
Metadata
- Authors
- Abi‐Said, D., Anaissie, E., Uzun, O., Raad, I., Pinzcowski, H., & Vartivarian, S.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Raad, Issam
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-06
- Volume
- 24
- Issue
- 6
- Pages
- 1122-1128
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2095696028
- Cited by
- 755
- References
- 4
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 5 · 2022: 11 · 2021: 3 · 2020: 14 · 2019: 9 · 2018: 8 · 2017: 18 · 2016: 10 · 2015: 21 · 2014: 28 · 2013: 17 · 2012: 35
- FWCI
- 22.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- Candida species, Candida albicans, Candida tropicalis, Candida krusei, Candida glabrata, fluconazole prophylaxis, leukemia, incidence trends, opportunistic fungal infection, cancer patients
- MeSH terms
- Adult, Aged, Candida, Candidiasis, Female, Humans, Male, Middle Aged, Retrospective Studies, Fluconazole, Fungemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.